1048 related articles for article (PubMed ID: 31639005)
21. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet.
Zheng F; Cai Y
Lipids Health Dis; 2019 Jan; 18(1):6. PubMed ID: 30611282
[TBL] [Abstract][Full Text] [Related]
22. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
[TBL] [Abstract][Full Text] [Related]
24. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
26. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
Li X; Wang Z; Klaunig JE
Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
[TBL] [Abstract][Full Text] [Related]
27. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
[TBL] [Abstract][Full Text] [Related]
29. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
30. Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis.
Li J; Xie S; Teng W
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010950
[TBL] [Abstract][Full Text] [Related]
31. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
Fu D; Cui H; Zhang Y
Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
[TBL] [Abstract][Full Text] [Related]
32. Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation.
Xia SF; Shao J; Zhao SY; Qiu YY; Teng LP; Huang W; Wang SS; Cheng XR; Jiang YY
Food Funct; 2018 Feb; 9(2):906-916. PubMed ID: 29309075
[TBL] [Abstract][Full Text] [Related]
33. A network pharmacology approach: Inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats.
Sun W; Liu P; Yang B; Wang M; Wang T; Sun W; Wang X; Zheng W; Song X; Li J
Phytomedicine; 2021 Jul; 88():153498. PubMed ID: 33640247
[TBL] [Abstract][Full Text] [Related]
34. Effect of folate supplementation on immunological and autophagy markers in experimental nonalcoholic fatty liver disease.
Youssry S; Kamel MA
Eur Cytokine Netw; 2019 Dec; 30(4):135-143. PubMed ID: 32096475
[TBL] [Abstract][Full Text] [Related]
35. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
36. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
[TBL] [Abstract][Full Text] [Related]
37. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
38. Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis.
Lizarazo D; Zabala V; Tong M; Longato L; de la Monte SM
J Gastroenterol Hepatol; 2013 Oct; 28(10):1660-8. PubMed ID: 23802886
[TBL] [Abstract][Full Text] [Related]
39. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
Liang L; Ye S; Jiang R; Zhou X; Zhou J; Meng S
Int Immunopharmacol; 2022 Mar; 104():108306. PubMed ID: 34999396
[TBL] [Abstract][Full Text] [Related]
40. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
Zhang H; Yang L; Wang Y; Huang W; Li Y; Chen S; Song G; Ren L
Life Sci; 2020 Sep; 257():118090. PubMed ID: 32679144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
